This section includes videos and an infographic in English and Spanish that can be downloaded or printed (in color or black and white) and used in shared decision-making with patients. These materials provide the basic facts about biosimilars in the treatment of IBD and how they compare to the originator biologics in short, simple formats plus a list of references for those who may want to dig deeper.
Disclosures
Ikuo Hirano, MD
- Research: Adare/Ellodi, Allakos, Arena, AstraZeneca, Meritage, Celgene/Receptos/BMS, Regeneron/Sanofi, and Shire/Takeda
- Consulting: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Phathom, Regeneron, Sanofi, and Shire/Takeda
Glenn T. Furuta, MD
- Research: NIH, Arena, Holoclara
- Founder: EnteroTrack
Nirmala P. Gonsalves, MD
- Consulting: Allakos, Astra-Zeneca, Sanofi-Regeneron, Abbvie, Knopp, Takeda
- Speaking: Takeda
- Up-to-Date: Royalties
